Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-03-07
Tempus AI, Inc.
Tempus AI sells genomic diagnostics, AI-enabled clinical software, imaging tools, and de-identified data products to providers and life sciences customers.
ai biotech healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated data flywheel with room to compound
A growing diagnostics base can feed a higher-margin data and AI software layer, giving the business a real chance to more than double equity value by 2031. The debate is whether reimbursement, regulation, and clinical workflow friction cap that re-rating.

Analysis

Thesis
Tempus can compound as a regulated data-rights platform: each diagnostic test refreshes a proprietary multimodal dataset that can be monetized again through biopharma analytics, imaging, and clinical workflow tools. If management sustains segment co-growth and turns that loop into durable EBITDA, equity value can still more than double by 2031 without needing a peak AI multiple.
Last Economy Alignment
Tempus benefits as AI makes multimodal data, biomarker discovery, and clinical interpretation more valuable, but monetization still depends on regulated assays, trust, and reimbursement.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.2x (from 5 most recent analyses)
Reasoning
The upside rests on Tempus becoming more than a testing company. A larger diagnostics base can feed a higher-margin data, imaging, and workflow layer, which should improve mix and justify a premium valuation versus plain diagnostics labs. I still haircut the terminal multiple versus today because regulation, reimbursement, and clinical adoption keep the business from scaling like pure software.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is conversion, not core science. Tempus must prove that diagnostics volume, data licensing, and AI applications reinforce each other fast enough to outgrow reimbursement friction and justify a premium multiple. A privacy or security issue, reimbursement setback, or simple slowdown in Data & Applications growth would pressure both margins and valuation at the same time.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.62
They own a hard-to-recreate medical data asset and the regulated tests that keep refreshing it, so cheaper AI makes their platform more useful rather than less. The catch is that hospitals, payers, and regulators still decide how fast that value turns into revenue.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$78.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case